Growing Popularity Of Applications Like Bone-graft Substitutes In The Global Biosurgery Market Is Aiding To Reach At A CAGR Of 8.51% By 2027.

Triton Market Research presents their Global Biosurgery Market report segmented by products (bone-graft substitutes, hemostatic agents, soft-tissue management, surgical sealing agents, and anti-adhesive agents); by applications (neuro and spine surgery, cardio and thoracic surgery, general surgery, and orthopedic surgery); by source type (natural or synthetic) and by geographical region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - discussing Industry Value Chain Analysis, Porter's 5 Force Analysis, Drivers, Restraints, Vendor Profiles, Global Market Size, Forecasts & Analysis (2019-2027).

Triton Market Research expects the global biosurgery market to witness a compound annual growth rate of 8.51% during the forecasted period 2019-2027. The market growth is being propelled by increased incidences of trauma-related wounds, the global increase in elderly population, rise in spinal fusion and joint reconstruction surgeries and increasing treatments for musculoskeletal disorders. Globally, there is an increased demand for biosurgery products as they are less expensive than other surgical products and provide more innovation.

The biosurgery products utilized globally in different surgical operations can be classified into anti-adhesive agents, hemostatic agents, surgical sealing agents, bone-graft substitutes, and soft tissue–management products, along with surgical synthetic and biological meshes. The bone graft substitutes currently account for a major share in this market. Bone grafting is a surgery performed to fix various problems of bones and joints. It is used for replacement of missing bone and repairing damaged bones or fractures.

Geographically, the global biosurgery market is dominated by North America which accounts for the highest revenue share. Increasing rates of chronic diseases such as hernia, neurologic and spinal disorders, and gynaecological and orthopaedic problems provide several opportunities in North America for biological products including anti-adhesive agents, haemostatic agents, surgical sealing agents, bone-graft substitutes, and soft tissue–management products. Also, the U.S. is one of the top countries for research and development in the world for bio-surgical products, which is a major plus point for this region.

However, there are many requirements that must be fulfilled before launching any novel biosurgery product. The FDA’s Center for Devices and Radiological Health (CDRH) is the main authority responsible for regulating firms that manufacture, repackage, relabel, and/or import medical devices sold in the U.S. Recently, it gave approval to an additional indication for Ethicon’s Evarrest Fibrin Sealant Patch to be used as an adjunct to haemostasis for preventing and controlling bleeding during adult liver surgery.

Market players such as Baxter International Inc., C.R. Bard Inc., Ethicon Inc., CryoLife Inc., Medtronic Plc, and Cohera Medical Inc. have developed numerous biosurgical products. Various strategies such as partnerships, mergers and acquisitions have been adopted by these players to garner additional market share. All these activities have resulted in increased product launch in the global biosurgery market.

For instance, in July 2016, Cohera Medical Inc. received Investigational Device Exemption (IDE) approval from the FDA to begin a clinical trial for its Sylys surgical sealant. This sealant device can be used to reduce anastomotic leakage during the first few days of healing. Other companies are also following suit and increasingly trying to promote their new products into this market.